FORT WORTH, Texas, Aug. 13 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), is excited about expanding upon the announcement that was made on Tuesday regarding the publication of (2) independent case reports utilizing their advanced wound care collagen product, CellerateRx(R), in the August edition of Advances in Skin and Wound Care. The case presentations were on recalcitrant diabetic wounds. The article will be available in its entirety for viewing on the company website, http://www.celleraterx.com in two weeks. In the meantime, the abstract may be viewed by going to http://www.woundcarejournal.com, click current issue (top left corner), then scroll down to article 370 "Activated, Type I Collagen (CellerateRx) and Its Effectiveness in Healing Recalcitrant Diabetic Wounds: A Case Presentation" and click abstract.
"We are excited about providing additional data regarding the cases that have successfully identified CellerateRx(R) as a very strong product in the management of diabetic wounds. We are also very excited about being able to provide eprints of the article on our site in the near term to enable our shareholders and customers to have the most up-to-date information on CellerateRx(R)," states Cathy Bradshaw, President of Wound Care Innovations, LLC.
Please feel free to contact us with any additional questions on the product or the development of our Company.
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at http://www.Celleraterx.com.
"Safe Harbor" Statement: Under The Private Securities Litigation Reform
Act of 1995: The statements in the press release that relate to the
company's expectations with regard to the future impact on the company's
results from new products in development are "forward-looking statements,"
within the meaning of the Private Securities Litigation Reform Act of 1995.
Since this information may contain statements that involve risk and
uncertainties and are subject to change at any time, the company's actual
results may differ materially from expected results. This document may
contain forward-looking statements concerning the Company's operations,
current and future performance and financial condition. These items involve
risks and uncertainties such as product demand, market and customer
acceptance, the effect of economic conditions, competition, pricing, the
ability to consummate and integrate acquisitions, and other risks and
uncertainties detailed in the Company's SEC filings. The Company undertakes
no obligation to revise any of these statements to reflect the future
circumstances or the occurrence of unanticipated events.
Product Information Shareholder Relations
Cathy Bradshaw Lucy Singleton
|SOURCE Wound Management Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved